Related Experiment Video
Updated: Jun 12, 2026
10:55
Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
Published on: October 31, 2025
Mycophenolate mofetil for interstitial lung disease in dermatomyositis
Pamela A Morganroth1, Mary Elizabeth Kreider, Victoria P Werth
1Philadelphia VA Medical Center, University of Pennsylvania, USA.
Arthritis Care & Research
|May 28, 2010
Summary
Mycophenolate mofetil shows promise in treating interstitial lung disease in dermatomyositis patients, leading to improved lung function and reduced symptoms. Further research is needed for definitive conclusions on this therapy.
Area of Science:
- Rheumatology
- Pulmonology
- Dermatology
Background:
- Interstitial lung disease (ILD) is a serious complication of dermatomyositis.
- Current treatment options for dermatomyositis-associated ILD have limitations.
- Mycophenolate mofetil (MMF) is an immunosuppressive agent with potential anti-fibrotic properties.
Observation:
- This retrospective case series evaluated 4 dermatomyositis patients with ILD treated with MMF and prednisone.
- Patients received MMF as a first-line therapy for their ILD.
- Pulmonary function and imaging data were analyzed for treatment outcomes.
Findings:
- Three out of four patients achieved complete normalization of pulmonary function tests and resolution of dyspnea after at least one year of MMF treatment.
- These patients were also able to reduce their prednisone dosage.
- One patient showed significant improvement in diffusing capacity for carbon monoxide and resolution of interstitial opacities on CT imaging.
Implications:
- Mycophenolate mofetil may represent a promising therapeutic option for dermatomyositis-associated interstitial lung disease.
- MMF could offer a steroid-sparing effect in managing this condition.
- Larger, prospective studies are warranted to confirm the efficacy and safety of MMF in this patient population.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:27Cryptococcal Meningitis
Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
01:22Myocarditis IV: Nursing Management
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...